Chimeric aptamers in cancer cell-targeted drug delivery

Critical Reviews in Biochemistry and Molecular Biology

Volumn 46, Issue 6, 2011, Pages 459-477

  Kanwar, Jagat R ^a   Roy, Kislay ^a   Kanwar, Rupinder K ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Aptamer; Chimera; Locked nucleic acid; Nanoparticles; SELEX; Si RNA; Targeted drug delivery

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOGENIN; APTAMER; C REACTIVE PROTEIN; COCAINE; DOPAMINE; HISTONE; LACTOFERRIN; LOCKED NUCLEIC ACID; LYSOZYME; MICRORNA; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SINGLE STRANDED DNA; SINGLE STRANDED RNA; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; THEOPHYLLINE; THROMBIN;

CANCER CELL; CANCER CELL CULTURE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG STABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVIEW;

ANIMALS; APTAMERS, NUCLEOTIDE; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; NEOPLASMS; SELEX APTAMER TECHNIQUE; TISSUE DISTRIBUTION;

BOVINAE;

EID: 81855218276     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2011.614592     Document Type: Review

References (149)

1. Alaoui AT et al. 2002. High afnity nucleic acid aptamers for streptavidin incorporated into bi-specifc capture ligands. Nucl Acids Res 30:45-49.
2. Alonso MJ, Gupta RK, Min C, Siber GR, Langer R. 1994. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 12:299-306. (Pubitemid 24071950)
3. Altieri DC. 2003. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22:8581-8589. (Pubitemid 38019195)
4. Baratchi S, Kanwar RK, Kanwar JR. 2010. Survivin: A target from brain cancer to neurodegenerative disease. Crit Rev Biochem Mol Biol 45:535-554.
5. Barciszewski J, Medgaard M, Koch T, Kurreck J, Erdmann VA. 2009. Locked nucleic acid aptamers. Methods Mol Biol 535:165-186.
6. Barry P, Robert JD, Gold L. 1996. High afnity nucleic acid ligands that discriminate between theophylline and cafeine. US Patent No 5, 580,737.
7. Bassett SE, Fennewald SM, King DJ, Li X, Herzog NK, Shope R, Aronson J F, Luxon BA, Gorenstein DG. 2004. Combinatorial selection and edited combinatorial selection of phosphorothioate aptamers targeting human nuclear factor-kappaB RelA/p50 and RelA/RelA. Biochemistry 43:9105-9115. (Pubitemid 38924444)
8. Becker RC, Chan MY. 2009. REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis. Curr Opin Mol Ter 11:707-715.
9. Berezovski M, Krylov SN. 2004. Using nonequilibrium capillary electrophoresis of equilibrium mixtures for the determination of temperature in capillary electrophoresis. Anal Chem 76:7114-7117. (Pubitemid 39600888)
10. Bivalkar-Mehla Svj, Mehla R, Abreha M, Kanwar JR, Tikoo A, Chauhan A. 2010. Viral Rna silencing suppressors (Rss): Novel strategy of viruses to ablate the host Rna interference (Rnai) defense system. Virus Res 155:1-9.
11. Bruno JG, Kiel JL. 2002. Use of magnetic beads in selection and detection of biotoxin aptamers by electrochemiluminescence and enzymatic methods. BioTechniques 32:178-80, 182.
12. Burke DH, Gold L. 1997a. RNA aptamers to the adenosine moiety of S-adenosyl methionine: Structural inferences from variations on a theme and the reproducibility of SELEX. Nucleic Acids Res 25:2020-2024. (Pubitemid 27303399)
13. Burke DH, Hofman DC, Brown A, Hansen M, Pardi A, Gold L. 1997b. RNA aptamers to the peptidyl transferase inhibitor chloramphenicol. Chem Biol 4:833-843. (Pubitemid 28000623)
14. Burke DH, Willis JH. 1998. Recombination, RNA evolution, and bifunctional RNA molecules isolated through chimeric SELEX. RNA 4:1165-1175. (Pubitemid 28413461)
15. Cheng C, Li LM. 2008. Inferring MicroRNA activities by combining gene expression with MicroRNA target prediction. Plos One 3:1-9.
16. Corgentech Inc (2004, 07 Dec). From Edifoligide (E2F Decoy) Phase 3 Trial For Peripheral Bypass Graft. http://www.medicalnewstoday. com/articles/17439. php.
17. Cai H, Reinisch K, Ferro-Novick S. 2007. Coats, tethers, Rabs, and SNAREs work together to mediate the intracellular destination of a transport vesicle. Dev Cell 12:671-682. (Pubitemid 46667749)
18. Cancerhelp.,Org.UK (2010). A trial of LY2181308 alongside chemotherapy for non small cell lung cancer. http://www. cancerhelp.org.uk/trials/a-trial-of- ly2181308-alongside-chemotherapy-for-non-small-cell-lung-cancer
19. Carlton J, Bujny M, Rutherford A, Cullen P. 2005. Sorting nexins-unifying trends and new perspectives. Trafc 6:75-82.
20. Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, Adamis A P. 2003. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci 44:290-299. (Pubitemid 36134287)
21. Centi S, Tombelli S, Palchetti I. & Mascini M. 2010. Development of an aptamer-based electrochemical sandwich assay for the detection of a clinical biomarker. Sensors and Lecture Notes in Electrical Engineering 54:207-210.
22. Chávez JL, Lyon W, Kelley-Loughnane N, Stone MO. 2010. Teophylline detection using an aptamer and DNA-gold nanoparticle conjugates. Biosens Bioelectron 26:23-28.
23. Chen Z, Li G, Zhang L, Jiang J, Li Z, Peng Z, Deng L. 2008. A new method for the detection of ATP using a quantum-dot-tagged aptamer. Anal Bioanal Chem 392:1185-1188.
24. Cheung CH, Sun X, Kanwar JR, Bai JZ, Cheng L, Krissansen GW. 2010. A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-a therapy. Cancer Cell Int 10:36.
25. Chi-Hong B, Chen KRD, Christopher PO, Cecilia DS, Meikana L, George AC, Michelle G, Francis EB, Audrey LF, Rachel M, Elizabeth FN. 2008. Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci USA 105:15908-15913.
26. Clinicaltrials.,Gov. 2010. A Study of Arc1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration. http://clinicaltrials.gov/ show/Nct00950638
27. Clinicaltrials.,Gov. 2009. Arc1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders. http:// clinicaltrialsfeeds.org/clinical-trials/show/Nct00632242
28. Collett JR, Cho EJ, Ellington AD. 2005. Production and processing of aptamer microarrays. Methods 37:4-15. (Pubitemid 41443371)
29. DI Primo C et al. 2007. Systematic screening of Lna/20-O-methyl chimeric derivatives of a Tar Rna aptamer. Febs Letters 581:771-774.
30. Ducongé F, Toulmé JJ. 1999. In vitro selection identifes key determinants for loop-loop interactions: RNA aptamers selective for the TAR RNA element of HIV-1. RNA 5:1605-1614.
31. Eckstein F, Gish G. 1989. Phosphorothioates in molecular biology. Trends Biochem Sci 14:97-100. (Pubitemid 19077544)
32. Eli G. 2010. Aptamer-targeted sirna to prevent attenuation or suppression of a T cell function. United States patent application, 12/752,802.
33. Ellington AD, Szostak JW. 1990. In vitro selection of RNA molecules that bind specifc ligands. Nature 346:818-822.
34. Ellington ADS, Szostak W. 1992. Selection in vitro of single-stranded Dna molecules that fold into specifc ligand-binding structures. Nature 355:850-852.
35. Enomoto L, Anderson PL, Li S, Edelstein CL, Weinber GA. 2011. Efect of Nucleoside and Nucleotide Analog Reverse Transcriptase Inhibitors on Cell-Mediated Immune Functions. AIDS Research and Human Retroviruses 27:47-55.
36. Eulberg D, Klussmann S. 2003. Spiegelmers: Biostable aptamers. Chembiochem 4:979-983. (Pubitemid 37267585)
37. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. 2004. Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res 64:7668-7672. (Pubitemid 39446893)
38. Farokhzad OC, Khademhosseini A, Jon S, Hermmann A, Cheng J, Chin C, Kiselyuk A, Teply B, Eng G, Langer R. 2005. Microfuidic system for studying the interaction of nanoparticles and microparticles with cells. Anal Chem 77:5453-5459. (Pubitemid 41266036)
39. Ferapontova EE, Gothelf KV. 2009. Efect of serum on an RNA aptamer-based electrochemical sensor for theophylline. Langmuir 25:4279-4283.
40. Freeman Rea. 2009. Self assembly of superamolecular aptamer structures for optical or electrochemical sensing. Analyst 134:653-656.
41. Gibbons JA, Kanwar RK, Kanwar JR. 2011. Lactoferrin and cancer in diferent cancer models. Front Biosci (Schol Ed) 3:1080-1088.
42. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. 1995. Biological efcacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311-1318.
43. Green LS, Jellinek D, Bell C, Beebe LA, Feistner BD, Gill SC, Jucker FM, Janjic N. 1995. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 2:683-695.
44. GU F et al. 2008. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. PNAS 105:2586-2591.
45. Haller AA, Sarnow P. 1997. In vitro selection of a 7-methyl-guanosine binding RNA that inhibits translation of capped mRNA molecules. Proc Natl Acad Sci USA 94:8521-8526. (Pubitemid 27335071)
46. Heckel A, Buf MC, Raddatz MS, Müller J, Pötzsch B, Mayer G. 2006. An anticoagulant with light-triggered antidote activity. Angew Chem Int Ed Engl 45:6748-6750. (Pubitemid 44600460)
47. Held DM, Kissel JD, Saran D, Michalowski D, Burke DH. 2006. Diferential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specifc steps during genome replication. J Biol Chem 281:25712-25722. (Pubitemid 44401960)
48. Hernandez FJ, Kalra N, Wengel J, Vester B. 2009. Aptamers as a model for functional evaluation of LNA and 2'-amino LNA. Bioorg Med Chem Lett 19:6585-6587.
49. Hertoghs KM, Ellis JH, Catchpole IR. 2003. Use of locked nucleic acid oligonucleotides to add functionality to plasmid DNA. Nucleic Acids Res 31:5817-5830. (Pubitemid 37442308)
50. Hicke BJ, Stephens AW. 2000. Escort aptamers: A delivery service for diagnosis and therapy. J Clin Invest 106:923-928.
51. Hillaireau H, Couvreur P. 2009. Nanocarriers' entry into the cell: Relevance to drug delivery. Cell Mol Life Sci 66:2873-2896.
52. Holliger P, Hudson PJ. 2005. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126-1136. (Pubitemid 41486394)
53. Homann M, Göringer HU. 1999. Combinatorial selection of high afnity RNA ligands to live African trypanosomes. Nucleic Acids Res 27:2006-2014. (Pubitemid 29209561)
54. Huertas CEM, Fessi H, Elaissari A. 2010. Polymer-based nanocapsules for drug delivery. International Journal of Pharmaceutics 383:113-142.
55. Hwang DW et al. 2010. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. The Journal of Nuclear Medicine 51:98-105.
56. Jenison SGRD, Pardi A, Polisky B. 1994. High-resolution molecular discrimination by RNA. Science 263:1425-1429. (Pubitemid 24137828)
57. Jensen KB, Atkinson BL, Willis MC, Koch TH, Gold L. 1995. Using in vitro selection to direct the covalent attachment of human immunodefciency virus type 1 Rev protein to high-afnity RNA ligands. Proc Natl Acad Sci USA 92:12220-12224. (Pubitemid 26014042)
58. JO MCN, JU M, Cheung E, Nishijima K, Robinson GS, Adamis AP, Shima DT. 2006. Inhibition of platelet-derived growth factor B signaling enhances the efcacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168:2036-2053. (Pubitemid 43825322)
59. Justin PD et al. 2009. Systemic administration of optimized aptamer-sirna chimeras promotes regression of Psma-expressing tumours. Nat Biotechnol 27:839-849.
60. Kanwar JR, Kamalapuram SK, Kanwar RK. 2010a. Targeting survivin in cancer: Patent review. Expert Opin Ter Pat 20:1723-1737.
61. Kanwar JR, Mahidhara G, Kanwar RK. 2010b. MicroRNA in human cancer and chronic infammatory diseases. Front Biosci (Schol Ed) 2:1113-1126.
62. Kanwar JR, Mohan RR, Kanwar RK, Roy K, Bawa R. 2010c. Applications of aptamers in nanodelivery systems in cancer, eye and infammatory diseases. Nanomedicine (Lond) 5:1435-1445.
63. Kanwar JR, Palmano KP, Sun X, Kanwar RK, Gupta R, Haggarty N, Rowan A, Ram S, Krissansen GW. 2008. 'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immunol Cell Biol 86:277-288. (Pubitemid 351430811)
64. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. 2001. Efects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 93:1541-1552. (Pubitemid 32998483)
65. Kanwar JR, Singh N, Kanwar RK. 2011. Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma. Nanomedicine (Lond) 6:701-714.
66. Kanwar RK, Cheung CH, Chang JY, Kanwar JR. 2010. Recent advances in anti-survivin treatments for cancer. Curr Med Chem 17:1509-1515.
67. Kanwar RK, Kanwar JR. 2011. Immunomodulatory lactoferrin in the regulation of apoptosis modulatory proteins in cancer. Protein & Peptide Letters. Accepted on 05-08-2011.
68. Kasahara Y, Kitadume S, Morihiro K, Kuwahara M, Ozaki H, Sawai H, Imanishi T, Obika S. 2010. Efect of 3'-end capping of aptamer with various 2',4'-bridged nucleotides: Enzymatic post-modifcation toward a practical use of polyclonal aptamers. Bioorg Med Chem Lett 20:1626-1629.
69. Katoh Y, Katoh M. 2008. Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). Int J Mol Med 22:271-275.
70. Kawata E, Ashihara E, Nakagawa Y, Kiuchi T, Ogura M, Yao H, Sakai K, Tanaka R, Nagao R, Yokota A, Takeuchi M, Kimura S, Hirai H, Maekawa T. 2010. A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro. Cancer Lett 294:245-253.
71. Keefe AD, Cload ST. 2008. SELEX with modifed nucleotides. Curr Opin Chem Biol 12:448-456.
72. Khaled A, Guo S, Li F, Guo P. 2005. Controllable self-assembly of nanoparticles for specifc delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett 5:1797-1808. (Pubitemid 41396168)
73. Kim E, Jung Y, Choi H, Yang J, Suh JS, Huh YM, Kim K, Haam S. 2010. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 31:4592-4599.
74. Kirkham M, Parton RG. 2005. Clathrin-independent endocytosis: New insights into caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta 1745:273-286. (Pubitemid 41330782)
75. Krissansen GW, Singh J, Kanwar RK, Chan YC, Leung E, Lehnert KB, Kanwar JR, Yang Y. 2006. A pseudosymmetric cell adhesion regulatory domain in the beta7 tail of the integrin alpha4beta7 that interacts with focal adhesion kinase and src. Eur J Immunol 36:2203-2214. (Pubitemid 44251765)
76. Kusser W. 2000. Chemically modifed nucleic acid aptamers for in vitro selections: Evolving evolution. J Biotechnol 74:27-38.
77. Laity JH, Lee BM, Wright PE. 2001. Zinc fnger proteins: New insights into structural and functional diversity. Curr Opin Struct Biol 11:39-46. (Pubitemid 32155550)
78. Lebars I, Richard T, Di Primo C, Toulmé JJ. 2007. LNA derivatives of a kissing aptamer targeted to the trans-activating responsive RNA element of HIV-1. Blood Cells Mol Dis 38:204-209. (Pubitemid 46518173)
79. Li W, Yang X, Wang K, Tan W, He Y, Guo Q, Tang H, Liu J. 2008. Realtime imaging of protein internalization using aptamer conjugates. Anal Chem 80:5002-8. (Pubitemid 351956308)
80. Lin L, Fu Q, Williams BA, Azzaz AM, Shogren-Knaak MA, Chaput JC, Lindsay S. 2009. Recognition imaging of acetylated chromatin using a DNA aptamer. Biophys J 97:1804-1807.
81. Lin Y, Nieuwlandt D, Magallanez A, Feistner B, Jayasena SD. 1996. High-afnity and specifc recognition of human thyroid stimulating hormone (hTSH) by in vitro-selected 2'-amino-modifed RNA. Nucleic Acids Res 24:3407-3414. (Pubitemid 26294453)
82. Lu D, Searles MA, Klug A. 2003. Crystal structure of a zinc-fnger-RNA complex reveals two modes of molecular recognition. Nature 426:96-100. (Pubitemid 37432548)
83. Lundberg P, El-Andaloussi S, Sütlü T, Johansson H, Langel U. 2007. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J 21:2664-2671. (Pubitemid 47372734)
84. Lünse CE, Michlewski G, Hopp CS, Rentmeister A, Cáceres JF, Famulok M, Mayer G. 2010. An aptamer targeting the apical-loop domain modulates pri-miRNA processing. Angew Chem Int Ed Engl 49:4674-4677.
85. Majumder P, Gomes KN, Ulrich H. 2009. Aptamers: from bench side research towards patented molecules with therapeutic applications. Expert Opin Ter Pat 19:1603-13.
86. Mathews L, Kanwar RK, Zhou S, Punj V, Kanwar JR. 2010. Applications of nanomedicine in antibacterial medical therapeutics and diagnostics. The Open Tropical Medicine Journal 3:1-9.
87. Mayer G, Kröck L, Mikat V, Engeser M, Heckel A. 2005. Light-induced formation of G-quadruplex DNA secondary structures. Chembiochem 6:1966-1970. (Pubitemid 41598167)
88. McNamara JO 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH. 2006. Cell type-specifc delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24:1005-1015. (Pubitemid 44215395)
89. Mendonsa SD, Bowser MT. 2004. In vitro evolution of functional DNA using capillary electrophoresis. J Am Chem Soc 126:20-21. (Pubitemid 38090319)
90. Miyachi Y, Shimizu N, Ogino C, Kondo A. 2010. Selection of DNA aptamers using atomic force microscopy. Nucleic Acids Res 38:e21.
91. Miyake Y, Togashi H, Tashiro M, Yamaguchi H, Oda S, Kudo M, Tanaka Y, Kondo Y, Sawa R, Fujimoto T, Machinami T, Ono A. 2006. MercuryII-mediated formation of thymine-HgII-thymine base pairs in DNA duplexes. J Am Chem Soc 128:2172-2173.
92. Molpeceres J, Chacón M, Guzmán M, Berges L, del Rosario Aberturas M. 1999. A polycaprolactone nanoparticle formulation of cyclosporin-A improves the prediction of area under the curve using a limited sampling strategy. Int J Pharm 187:101-113. (Pubitemid 29435977)
93. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G. 1997. A new peptide vector for efcient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 25:2730-2736. (Pubitemid 27299785)
94. Morris MC, Depollier J, Mery J, Heitz F, Divita G. 2001. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19:1173-1176. (Pubitemid 33115705)
95. NG EWM, Calias P, Cunningham ETJR, Guyer DR, Adamis AP. 2006. Pegaptanib, a targeted anti-Vegf aptamer for ocular vascular disease. Nature Reviews 5:123-132.
96. Nutiu R, Li Y. 2005. Aptamers with fuorescence-signaling properties. Methods 37:16-25.
97. Ohk SH, Koo OK, Sen T, Yamamoto CM, Bhunia AK. 2010. Antibody-aptamer functionalized fbre-optic biosensor for specifc detection of Listeria monocytogenes from food. J Appl Microbiol 109:808-817.
98. Orum H, Wengel J. 2001. Locked nucleic acids: A promising molecular family for gene-function analysis and antisense drug development. Curr Opin Mol Ter 3:239-243. (Pubitemid 32624572)
99. Pastor F, Kolonias D, Giangrande PH, Gilboa E. 2010. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 465:227-230.
100. Perret E, Lakkaraju A, Deborde S, Schreiner R, Rodriguez-Boulan E. 2005. Evolving endosomes: How many varieties and why? Curr Opin Cell Biol 17:423-434. (Pubitemid 40968074)
101. Petersen M, Wengel J. 2003. LNA: A versatile tool for therapeutics and genomics. Trends Biotechnol 21:74-81. (Pubitemid 36165007)
102. Qian J, Lou X, Zhang Y, Xiao Y, Soh HT. 2009. Generation of highly specifc aptamers via micromagnetic selection. Anal Chem 81:5490-5495.
103. Riechmann L, Clark M, Waldmann H, Winter G. 1988. Reshaping human antibodies for therapy. Nature 332:323-327. (Pubitemid 18091075)
104. Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjic N. 1998. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273:20556-20567. (Pubitemid 28377626)
105. Russell SJ, Llewelyn MB, Hawkins RE. 1992. The human antibody library. BMJ 304:585-586.
106. Sampson T. 2003. Aptamers and Selex: The technology. World Patent Information 25:123-129.
107. Seferos DS, Giljohann DA, Rosi NL, Mirkin CA. 2007. Locked nucleic acid-nanoparticle conjugates. Chembiochem 8:1230-1232. (Pubitemid 47171986)
108. Sengle G, Jenne A, Arora PS, Seelig B, Nowick JS, Jäschke A, Famulok M. 2000. Synthesis, incorporation efciency, and stability of disulfde bridged functional groups at RNA 5'-ends. Bioorg Med Chem 8:1317-1329. (Pubitemid 30398453)
109. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, Sefah K, Yang CJ, Tan W. 2006. Aptamers evolved from live cells as efective molecular probes for cancer study. Proc Natl Acad Sci USA 103:11838-11843. (Pubitemid 44215773)
110. Shaw BR, Moussa L, Sharaf M, Cheek M, Dobrikov M. 2008. Boranophosphate siRNA-aptamer chimeras for tumor-specifc downregulation of cancer receptors and modulators. Nucleic Acids Symp Ser (Oxf) 53:655-656.
111. Shen Y, Jin E, Zhang B, Murphy CJ, Sui M, Zhao J, Wang J, Tang J, Fan M, Van Kirk E, Murdoch WJ. 2010. Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery. J Am Chem Soc 132:4259-4265.
112. Su S, Nutiu R, Filipe CD, Li Y, Pelton R. 2007. Adsorption and covalent coupling of ATP-binding DNA aptamers onto cellulose. Langmuir 23:1300-1302.
113. Shigdar S, Lin J, Yu Y, Pastuovic M, Wei M, Duan W. 2011. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 102:991-998.
114. Silahtaroglu A, Stenvang J. 2010. MicroRNAs, epigenetics and disease. Essays Biochem 48:165-185.
115. Smirnov I, Shafer RH. 2000. Lead is unusually efective in sequence-specifc folding of DNA. J Mol Biol 296:1-5.
116. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA, Lieberman J. 2005. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23:709-717. (Pubitemid 41716361)
117. Sooter LJ, Riedel T, Davidson EA, Levy M, Cox JC, Ellington AD. 2001. Toward automated nucleic acid enzyme selection. Biol Chem 382:1327-1334. (Pubitemid 32976492)
118. Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. 2008. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res 68:2358-2365. (Pubitemid 351521810)
119. Stenmark H, Olkkonen VM. 2001. The Rab GTPase family. Genome Biol 2:REVIEWS3007.
120. Stuart RK, Stockerl-Goldstein K, Cooper M, Devetten M, Herzig R, Medeiros B, Schiller G, Wei A, Acton G, Rizzieri D. 2009. Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (Aml). J Clin Oncol 27:7019.
121. Sullenger BA, Gallardo H F, Ungers GE, Gilboa E. 1990. Overexpression of TAR sequences renders cells resistant to human immunodefciency virus replication. Cell 63:601-608.
122. Tong R, Yala L, Fan TM, Cheng J. 2010. The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells. Biomaterials 31:3043-3053.
123. Tsimikas S, Willerson JT, Ridker PM. 2006. C-reactive protein and other emerging blood biomarkers to optimize risk stratifcation of vulnerable patients. J Am Coll Cardiol 47:C19-C31.
124. Tuerk C, Gold L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510.
125. Ulrich H, Magdesian MH, Alves MJ, Colli W. 2002. In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion. J Biol Chem 277:20756-20762. (Pubitemid 34967381)
126. Van der Goot FG, Gruenberg J. 2006. Intra-endosomal membrane trafc. Trends Cell Biol 16:514-521.
127. Vater A, Jarosch F, Buchner K, Klussmann S. 2003. Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identifed by a novel approach: Tailored-SELEX. Nucleic Acids Res 31:1-7.
128. Wagner-Whyte JKS, Preiss J, Kurz JC, Olson K, Hatala P, Boomer RM, Fraone JM, Brosnan N, Makim A et al. 2007. Discovery of a potent, direct thrombin inhibiting aptamer. J Tromb Haemost (Isth Congress abstracts).
129. Wang AZ, Bagalkot V, Vasilliou CC, Gu F, Alexis F, Zhang L, Shaikh M, Yuet K, Cima MJ, Langer R, Kantof PW, Bander NH, Jon S, Farokhzad OC. 2008. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 3:1311-1315.
130. Wang C, Zhang M, Yang G, Zhang D, Ding H, Wang H, Fan M, Shen B, Shao N. 2003. Single-stranded DNA aptamers that bind diferentiated but not parental cells: Subtractive systematic evolution of ligands by exponential enrichment. J Biotechnol 102:15-22. (Pubitemid 36369199)
131. Wang W, ling-yun J. 2009. Progress in aptamer screening methods. Chin J Anal Chem 37:454-460.
132. Wang Y, Pu KY, Liu B. 2010a. Anionic conjugated polymer with aptamer-functionalized silica nanoparticle for label-free naked-eye detection of lysozyme in protein mixtures. Langmuir 26:10025-10030.
133. Wang Z, Ho PC. 2010b. A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials 31:7115-7123.
134. Weiss TC, Zhai GG, Bhatia SS, Romaniuk PJ. 2010. An RNA aptamer with high afnity and broad specifcity for zinc fnger proteins. Biochemistry 49:2732-2740.
135. White R, Rusconi C, Scardino E, Wolberg A, Lawson J, Hofman M, Sullenger B. 2001. Generation of species cross-reactive aptamers using "toggle" SELEX. Mol Ter 4:567-573.
136. Wlotzka B, Leva S, Eschgfäller B, Burmeister J, Kleinjung F, Kaduk C, Muhn P, Hess-Stumpp H, Klussmann S. 2002. In vivo properties of an anti-GnRH Spiegelmer: An example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci USA 99:8898-8902. (Pubitemid 34693655)
137. Wolfgang P, Tasset D, Janic N, Gold L, Kirschenheuter GP. 1997. High afnity nucleic acid ligand containing modifed nucleotides. US Patent No 5, 660,985.
138. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. 2009. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 8:526-33.
139. Wu L, Curran JF. 1999. An allosteric synthetic DNA. Nucleic Acids Res 27:1512-1516. (Pubitemid 29206294)
140. Xie J, Chen K, Huang J, Lee S, Wang J, Gao J, Li X, Chen X. 2010. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials 31:3016-3022.
141. XU W, LU Y. 2010. Label-Free Fluorescent Aptamer Sensor Based on Regulation of Malachite Green Fluorescence. Anal Chem 82:574-578.
142. Xua Z, Takanori T, Riordana JF., and HU GF. 2002. The nuclear function of angiogenin in endothelial cells is related to rrna production. Biochemical and Biophysical Research Communications 294: 287-292.
143. Yang X, Bassett SE, Li X, Luxon BA, Herzog NK, Shope RE, Aronson J, Prow TW, Leary J F, Kirby R, Ellington AD, Gorenstein DG. 2002a. Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing. Nucleic Acids Res 30:e132.
144. Yang X, Bassette SE, LI X, Luxon BA, Herzog NK, Shope RE, Aronson J, Prow TW, Leary J F, Kirby R, Ellington AD, Gorenstein DG. 2002b. Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid Pcr-based sequencing. Nucleic Acids Res 30:1-8.
145. Yang X, Li N, Gorenstein DG. 2011. Strategies for the discovery of therapeutic aptamers. Expert Opinion on Drug Discovery 6:75-87.
146. Zhang CY, Johnson LW. 2009. Single quantum-dot-based aptameric nanosensor for cocaine. Anal Chem 81:3051-3055.
147. Zhou J, LI H, Zhang J, Piotr S, Rossi J. 2011. Development of cell-type specifc anti-Hiv gp120 aptamers for sirna delivery. J Vis Exp 23: pii: 2954.
148. Zhou J, Li H, Li S, Zaia J, Rossi JJ. 2008. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ter 16:1481-1489.
149. Zhou J, Rossi JJ. 2010. Aptamer-targeted cell-specifc RNA interference. Silence 1:4.